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Abstract: People’s views about medicines reuse are being examined in a handful of qualitative
studies and this commentary adds to that work by drawing on our own discussions with groups
of stakeholders in the UK in the past two years. The reuse of medicines within the community
pharmacy setting is not permitted in the UK but our multidisciplinary team anticipates that this
position will change in the coming years as medication shortages and worries about environmental
waste and financial losses from the destruction of unused medicines are brought to the fore. Indeed,
for many stakeholders, the issue of waste is a strong feature of conversations about medicines reuse.
In addition to this, stakeholders identify the numerous barriers to medicines reuse in the UK. This
includes the current uncertainty about the quality of unused medicines returned to pharmacies,
which could otherwise be reused. However, stakeholders have also been very willing to propose
solutions to a range of existing barriers. Our commentary draws on stakeholder meetings to elaborate
the range of views about medicines reuse within a UK context. The challenge is to move forward
from these views to advance the technologies that will facilitate medicines reuse practically as well
as legally.
Keywords: medicines; reuse; recycle; medicines reuse; attitudes
1. Introduction
A limited number of studies have examined people’s views about the concept of
‘medicines reuse’ [1–4] and the purpose of this commentary is to add to this body of knowl-
edge by reporting on our own discussions about the topic with groups of stakeholders in
the UK in the past 24 months.
The concept of ‘medicines reuse’ itself is open to different interpretations and defini-
tions. For example, some might understand it to relate to reusing a patient’s own medicines
when they are admitted to a hospital ward [5]; or the concept might be related to the recy-
cling of medicinal components or packaging in future manufacturing processes [6]. The
phrase medicines reuse has also been used to refer to the repurposing of old drugs for new
conditions. A number of related terminologies also exist, including re-dispense, recycle,
redistribute and reverse flow. These ideas and related concepts, although important, are
not the focus of the current paper. Here, we use the term ‘medicines reuse’ to mean the
idea that within a community pharmacy context, “medication returned by one patient can
be dispensed by a pharmacist to another patient (instead of disposal as waste–which is
what currently takes place)”. Our paper is focused within a UK context, where pharma-
cists working within community pharmacies are not permitted to reuse medicines. What
prevents medicines reuse in this setting is a combination of the law, professional guidance
and past precedence.
In the UK, apparently how a medicine is sourced is not generally relevant as long as a
medicine is supplied in accordance with the relevant prescription, for the specific purposes
of part 12 of the Human Medicines Regulation 2012 [7]. However, reusing medicines
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reportedly invalidates the terms and conditions under which medicines are supplied
from wholesalers [8]. Additionally, because legislation governing the supply of medicines
requires persons trading medicines (other than directly supplying to patients) to hold a
wholesale dealer’s license [unless supplies are small, take place occasionally, are not-for-
profit and not for onward wholesale distribution], this legislation also limits the receipt and
redistribution of returned medicines between different units/legal entities along a supply
chain (e.g., from one pharmacy to another) [9]. Furthermore, under normal circumstances,
medicines reuse is not recommended by the Department of Health because the quality of
any medicine that has left the pharmacy cannot be guaranteed [10,11]. In fact, in the UK,
none of the regulatory and professional bodies currently support the reuse of medicines
within the community pharmacy setting. This includes the Medicines and Healthcare
Products Regulatory Agency (MHRA), the Association of British Pharmaceutical Industries
(ABPI), the General Pharmaceutical Council (GPhC), the National Health Service (NHS),
the British Medical Association (BMA), and the Royal Pharmaceutical Society (RPS). Our
research group, however, is investigating the sustainability of this position.
Based on existing knowledge about pharmacy and the technology that might be inte-
grated within pharmaceutical packaging, our multidisciplinary team Reuse of Medicines
through Informatics, Networks and Sensors (ReMINDS) (www.reading.ac.uk/ReMINDS,
accessed on 14 April 2020) is composed of academics from the pharmacy, computer science
and biomedical engineering fields at the University of Reading. ‘ReMINDS’ communicates
our opinion on medicines reuse candidly (we are pro researching medicines-reuse) so
our paper is arranged as a commentary rather than a research paper, the aim being to
present new viewpoints on an existing problem, while also drawing on original data. Here,
we draw on key themes conveyed to our group by a range of stakeholders in meetings
organized to discuss medicines reuse, while acknowledging that our paper is imbued with
personal opinion, in line with Berterö’s definition of a commentary [12].
We draw on our discussions with a range of stakeholders that includes young people,
future pharmacists, pharmacists working within the primary-care, community, hospital,
and homecare settings, pharmaceutical industry representatives, specialists in medicines
supply, patients, and researchers.
2. The Wastage of Medicines
Medicines reuse as a concept stems from the problem of medication waste. After all, if
there was zero medication wastage, there would be no medicines to reuse. Thus, a range of
ideas about medicines reuse are expressed by people, directly in relation to the creation
and prevention of medication waste.
A range of practices and settings are thought to contribute to medication waste. For
example, using multi-compartment compliance aids (MCCAs) as a practice is thought to
be wasteful; in MCCAs, individual doses, having been removed from their packaging, are
placed with other medicines within distinct compartments a month or more in advance of
actual consumption, rendering the medicines ‘expended’ as soon as the MCCA is prepared.
Then if a patient’s medication regimen is changed (e.g., a medication is discontinued),
the entire content of their MCCA becomes unusable for that patient—this is because it
is too risky to remove individual discontinued tablets from the compartments (risk of
error) so the entire contents have to be discarded once the regimen changes. MCCAs are
utilized widely within care homes, where there is also a notion by some stakeholders that
care-home staff contribute to the wastage of medicines by excessive reordering and the
stockpiling of medicines.
Outside of formal care settings, another factor associated with medication waste is
medication non-adherence, where patients fail to fully follow the dosage instructions of
their medication, for example by not taking their medicines at all or failing to complete the
full course. The reasons for non-adherence are complex, multi-factorial and well researched
but some noteworthy insights from our patient stakeholders include the need to create
conditions that allow patients to disclose their real medication-taking patterns, and to
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address their fear, disinterest or lack of understanding about medicines, some of which
are potentially engendered, it seems, through the physical appearance (design/text) of
medicinal packaging.
An additional behaviour recognized and discussed by our stakeholders is the unnecessary/over-
ordering of medication, for example patients ordering large pack sizes, and stockpiling
medication, or over/inappropriate prescribing by doctors. This issue is especially impor-
tant in the UK since patients are sometimes seen not to be ‘accountable’ for behaviours
such as over-ordering, because many do not directly pay for their medication and bear
none of the financial costs. There is arguably then no real barrier to intentional or unin-
tentional medication stockpiling, with some of the people we have spoken to suggesting
that notifying patients about the monetary cost (albeit to the NHS) of their medicines (e.g.,
printing the price on the medicinal packet) might incentivize more responsible re-ordering
behaviours—or that in any case alerting patients of their responsibility to reduce the NHS
medicines spend is a worthwhile activity.
Doctors, pharmacists and other health professionals are also considered key actors
who can reduce medicines waste by ‘taking responsibility’ for more sustainable practices.
For example, by checking, discussing and challenging quantities and medicines being
re-ordered, completing medication reviews to ensure rational prescribing, prescribing
lower quantities for more expensive medicines or medicines that are new to patients, and
ensuring better stock control (including liaising with wholesalers and delivery companies)
to avoid accumulating short-dated items (including on hospital wards) or ending up with
medicines that are kept at the wrong storage temperature. Related to this is the notion of
deprescribing (stopping superfluous medicines), which some patients and doctors avoid
out of fear (of therapeutic repercussions). Finally, as patients’ own drugs (PODs) can still
be used if they are admitted to hospital, another challenge is to ensure patients take their
current medicines to hospital, to avoid duplicate dispensing, especially important where
people have multiple admissions to hospital within a short period of time. Of course, this
is not to deny that some PODs are judged to be of insufficient quality by hospital staff and
re-dispensed in any case.
3. Barriers to Medicines Reuse
Similar to that reported elsewhere, our stakeholders had some concerns about medicines
reuse. This included questions about the quality and safety of returned medicines and
how these might be checked for suitability; and whether patients and consumers really
store their medicines correctly at home, especially medicines requiring cold storage—and
how people might be educated to do so. Our stakeholders recognized the potential for
errors or contamination to occur within the supply chain. Further, they wondered about
the cleanliness and potential for contamination of returned medication packs.
One of the concerns about medicines reuse relates to the practicality of operating such
a scheme in UK community pharmacies. Community pharmacists have limited time for
additional services, meaning that the addition of a medicines reuse scheme would doubtless
require effective resourcing and incentivization. It also necessitates additional guidance
and standard operating procedures for the receipt, separate storage, quality-assurance,
and supply of reusable medicines within relatively small pharmacy spaces. National
pharmacy bodies, for example, would be expected to publish consensus guidelines on
medicines reuse. Or the NHS might consider taking back returned medication for storage
and re-distribution. An additional challenge within community pharmacies relates to
the reimbursement of prescription costs and the audit trail needed to prevent duplicate
payments to pharmacies, while ensuring pharmacies are paid for the cost of administering
medicines reuse.
There is also an expectation for medicines reuse to be financially logical, with imple-
mentation costs having to balance against the cost of the original medication. For example,
any additional technology that might track the medicine’s storage conditions, batch number,
manufacturing date/product age, expiry date, etc., to manage resupply, should reasonably
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be cost-effective. Stakeholders also highlight the potential paradox of having to add to
a medicine’s carbon footprint in order to reduce its waste—the environmental harm of
medicines reuse (e.g., via any additions to the packaging) must thus balance against that
created by the medicine’s potential wastage if unused.
Two points came up specifically when we spoke to younger people about medicines
reuse. Some conceptualized reuse as the process of taking back medicines and re-extracting
the constituent elements. For packaged medicines, they thought that these are already
routinely sent to other (poorer) countries for their use, but this practice is discouraged by
the World Health Organisation which sees it as operating double standards.
Stakeholders pose other relevant questions within the UK context, including whether
multiple re-use (re-dispensing) of a medicine might be permitted, and how recall of
medicines might affect re-dispensed medicines. Another important issue is how cur-
rent legislation to hold a wholesale dealer’s licence impacts on medicines reuse across
different sections of the NHS.
A related matter concerns the falsified medicines directive (FMD), which describes a
set of measures introduced in the European Union for the regulation of medicines trade, to
prevent the appearance of fake medicines in the legal supply chain. February 2019 saw the
implementation of two specific safety features on medicines determined by FMD; a unique
identifier (a 2D data matrix code with product code, serial number, batch number, expiry
date) on medicinal packaging scannable at fixed points along the supply chain, and tamper
evident features (anti-tampering devices) on the pack. Thus, medicines can be verified in
their movement through the supply chain, and ‘decommissioned’ at the final point, on
supply to the patient. The stakeholders we engaged with duly ask how medicines then
might be placed back within the supply chain in light of FMD, and how the safety features
determined by FMD might be harvested to verify medicines for reuse. However, FMD will
no longer apply in the UK following its exit from the European Union in 2021, and while
this negates the need to ‘re-commission’ a medicine, the absence of safety features that
might prevent falsified medicines from entering the supply chain is a less constructive step
for medicines reuse.
4. Towards Solutions
Medicines reuse is not currently permitted in the UK but there have been ample
questions and ideas from our stakeholders on how to promote engagement with such a
scheme in the future. Some questions are, for example, how people might be incentivized
to return their unused medicines to pharmacies in the first place, especially within the shelf
life of the product. And how they might be educated to store their medication correctly at
home to start with. How the stigma around returning medicines to pharmacies might be
reduced—after all, these are medicines that would have been ordered/accepted but then
left unused. Further, is there a need to take consent before supplying ‘reused’ medicines?
How might we tackle negative perceptions about receiving what some might consider to be
‘second-hand medicines’, such that medicines reuse becomes socially acceptable, or indeed
an obligation in light of eco-friendly movements? Perhaps in the future there might even
be a system where people actively ‘opt out’ of receiving medicines within a reuse scheme.
Suggestions for changing popular opinion and social norms include teaching about
the importance of medicines reuse, communicating success stories, and reshaping mis-
conceptions about ‘re-used’ medicines. Stakeholders believe incentivizing uptake, or at
least quantifying the overall benefits of medicines reuse could encourage engagement. For
example, reusing medicines to prevent medicines shortages is a logical aim. Patients also
want clearer information about the current fate of medicines returned to pharmacies. Other
suggestions are to learn from existing groups such as ‘free cycle’, and to train pharmacists
and other staff to promote engagement with medicines reuse, and indeed sustainable
pharmacy more broadly, and engaging with popular media, celebrity advocates and social
media influencers. The use of social media and technology (e.g., smartphones) is seen as
plausible, indeed inevitable but patients also express that any developments in this area
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should be inclusive of older people, who use medicines the most, and poorer patients who
might lack access to the newest smartphones.
The support of a range of official bodies too is seen as important for sanctioning
medicines reuse in the first place, none of which currently approve medicines reuse within
the community pharmacy setting. For example, engaging with medicines reuse might
become a part of the community pharmacy contract and embedded within the pharmacy
professional standards. Or administering medicines reuse might formally become one
of the responsibilities of support staff within a pharmacy. Stakeholders suggest drawing
on the experience of similar schemes in Greece [13] and the US [14] to overcome existing
barriers to medicines reuse, and aiming to make medicines reuse as acceptable as reusing
coffee cups and plastic bags.
Pharmaceutical companies are seen to play a key role and perhaps there could even
be tax breaks for companies proactively changing their practices to facilitate reuse; or other
incentives in lieu of their social responsibility. For example, pharmaceutical companies are
recognized for holding primary raw data relating to the stability of medicines under differ-
ent storage conditions—gaining access to these data might enable researchers to model and
predict the integrity of medication stored in different home environments, to help define
medication reuse criteria. Pharmaceutical companies might also explore whether medica-
tion packaging could be modified to colour-code sensitivity to environmental conditions,
increase tolerance to these conditions, accommodate time/temperature indicators or other
technology within the surface, or become more sustainable in itself. They might extend the
usable shelf life of medicines. They might invest in the development of a secure supply
chain for the return of medicines, sustainable technology that monitors medicine integrity
during storage and use, or indeed tracks its whereabouts, and provide assurances about
the safety, quality and cleanliness of returned medicines. Such technology would need
to be secure and ensure the privacy, and even liberty of users. It would also need to be
mindful of the primary users of medicines—for example, to prevent creating alarm if a
visual quality indicator shows a potentially ‘invalidated’ medicine during first use.
Hospital pharmacies are recognized for their policies on medicines reuse (for us-
ing PODs), and pharmacies in general have risk management tools, which stakeholders
expressed would be useful to learn from.
In terms of legislation, our stakeholders recognized the importance of engaging with
the various professional and regulatory bodies to enable medicines reuse, recognizing the
time and effort that would be required. Activities might include lobbying the MHRA for
an exemption that would allow medicines to be reused within the community pharmacy
setting; or illustrating potential cost savings to the Department of Health, at least for
high-cost items or where drugs are vulnerable to shortages.
5. Discussion
Our stakeholders’ ideas about the wastage of medicines can be summarized as relating
to practices around MCCAs, especially in care homes, medication non-adherence, over-
ordering, over-prescribing, improper stock control and inadequate use of PODs. Their
concerns about medicines reuse relate to the quality and safety of returned medicines,
pharmacy resources and incentivization to deal with the process, the cost-benefits of such
a scheme, and legislative barriers. Finally, their proposed solutions centre on educating
and incentivizing the public, removing stigma around returning and reusing medicines,
defining consent processes, using technology and social media, engaging with official
bodies and the pharmaceutical industry, learning from existing practices in hospitals and
lobbying regulators to change the law.
The issues identified as contributing to waste have long been recognized by others
and in fact mirror many of the findings of a seminal report on the scale, causes and costs
of waste medicines published in 2011 [15]. Indeed, the problem of medication waste is
one of the main reasons for debating medicines reuse. This is alongside the high cost of
medication, for example expensive cancer drugs in developed countries [16] and the cost of
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a range of other drugs for chronic and communicable diseases in developing countries such
as India [17]. A small pilot in Singapore has also identified the huge potential for medicines
reuse to reduce medication wastage and costs [18]. Researchers examining the benefit of
long-term donation programmes in Europe, Africa and Latin America, against WHO’s
formal advice to withhold such donations, also report a decrease in expenditure by both
patients and health facilities [19]. The issue of lack of accountability for the over-ordering
of medicines identified by our stakeholders associated with free prescriptions has also been
debated before, with one suggestion being to charge a nominal £1 fee for prescription items
to create a symbolic contract for patients to take their medicines more responsibly [20].
Some of the concerns relating to medicines reuse expressed by our stakeholders, as
well as their proposed solutions, also feature in the limited number of studies that have
systematically examined medication reuse. For example, Bekker and colleagues who exam-
ined views about medicines reuse in The Netherlands in 2014/15 identified two central
requirements for the re-dispensing of returned medicines; namely, patient willingness to
use and trust re-dispensed medicines and guaranteed product quality of re-dispensed
medicines [2]. System requirements in that study were identified as relating to legal feasi-
bility, financial aspects that should be taken into account and the roles stakeholders can
fulfil [2]. Interestingly, in 2014 Liou and colleagues devised a quality control programme to
ensure the safe recycling of metered dose inhalers within a hospital setting, focusing on
microbial decontamination of the partially used devices [21]. When McRae and colleagues
interviewed pharmacists in the UK about medicines reuse in 2014, they identified a range
of criteria to be met for pharmacists to potentially accept the redistribution of tablet and
capsule medication: “protection for pharmacists; guidance from the professional regulator;
tamper evident seals; ‘as new’ packaging; technologies to indicate inappropriate storage
and public engagement” [22]. Our own findings from interviews with members of the
public in the UK exploring medicines reuse beliefs in 2016 was structured around the theory
of planned behaviour [3]. We reported views on the potential economic and environmental
benefits of medicines reuse alongside people’s worries about medication stability and safety.
Our participants then also wondered if pharmacists had the time and storage space to
dedicate to medicines reuse. The physical characteristics of reused medicines, and quality
assurance and logistics of reuse processes were also seen to enable/obstruct engagement in
medicines reuse [3]. Thus, our stakeholders’ views outlined here appear to chime with the
concerns expressed by others in the past, and appear to be valid and reasonable to address.
While the number of studies in this field are limited, it is also clear that once people
are consulted, there is an appetite for exploring how to make medicines reuse safe, and a
limited number of ideas on how to do so in practice. One of the ideas that appears to be
unique to our own exploration of views here is to engage pharmaceutical companies in
sharing their raw stability data to be programmed into a system for monitoring the impact
of storage conditions on the continued stability of medication stored in a patient’s home.
We also found it interesting that when talking to our younger stakeholders, they imagined
medicines reuse was already taking place, albeit at least via donations to developing
countries. What is important about our work is that is brings together the views of a range
of participants and reflects the latest thinking in this area. However, it is also interesting to
note that as far back as 2007, Mackridge and Marriott spotted the potential that by using
“modern packaging techniques, including tamper-evident seals and ‘smart’ labels that
react to temperature and humidity, it would be possible to identify inappropriately stored
medicines” [23].
6. What Next
Alongside stakeholder consultations described here and elsewhere [3], we have been
progressing some of the practical ideas relating to medicines reuse within our multidis-
ciplinary ReMINDS team. A review of the literature has allowed us to suggest a novel
ReMINDS ecosystem as a solution for reusing returned prescribed medicines [24]. This
system relies on active sensing technologies integrated with the Internet of Things plat-
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form to validate the quality and safety of medicines while interconnecting the relevant
stakeholders. Additionally, we have developed the prototype for a novel digital time,
temperature and humidity indicator using smart sensors with cloud connectivity as the
key technology for verifying and enabling the reuse of returned medicines [25]. The past
year has also seen a global pandemic impacting on the supply of medicines which in the
UK has resulted in the temporary approval of medicines reuse within the hospice and care
home sectors [26]. Our challenge now is to learn from the reuse of medicines within these
settings and continue to explore the technological ways in which medicines reuse can be
further progressed.
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